Cointime

True North Therapeutics

company

About

True North Therapeutics is a pioneering biotechnology company selectively inhibiting the Complement pathway for diseases.

  • 11 - 50

Highlights

Total Funding Amount
$40M
Funding Rounds
1
Investors
1

Details

Last Funding Type
Series C
Last Funding Money Raised
$40M
Industries
Biotechnology,Clinical Trials,Health Care
Founded date
Jan 1, 2013
Number Of Employee
11 - 50
Operating Status
Active

True North Therapeutics is a pioneering biotechnology company selectively inhibiting the Complement pathway for diseases of high unmet clinical need. The company’s lead monoclonal antibody, TNT009, targets the Classical Complement pathway, enabling selective inhibition of downstream phagocytosis, inflammation, and cell lysis. True North is currently focused on Complement-mediated rare diseases in the hematologic, kidney transplant, dermatology, and neurological space. True North was formed in 2013 as a spin-out of iPierian.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$40M
True North Therapeutics has raised a total of $40M in funding over 2 rounds. Their latest funding was raised on Dec 3, 2015 from a Series C round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Dec 3, 2015 Series C $40M 1 — — Detail

Investors

Number of Lead Investors
Number of Investors
—
1
True North Therapeutics is funded by 1 investors. Cowen Investment Management are the most recent investors.
Investor Name Lead Investor Funding Round
Cowen Investment Management — Series C
Cointime
Chủ Đề
Công Ty